Compounds > 3,4-dihydroxyphenylacetic acid

3,4-dihydroxyphenylacetic acid and zonisamide

3,4-dihydroxyphenylacetic acid has been researched along with zonisamide in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (33.33)	18.2507
2000's	2 (33.33)	29.6817
2010's	2 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fukushima, Y; Hirano, T; Ishida, M; Kaneko, S; Kondo, T; Okada, M; Otani, K	1
Fukushima, Y; Hirano, T; Kaneko, S; Kondo, T; Mizuno, K; Okada, M; Otani, K	1
Gluck, MR; Granson, H; Santana, LA; Yahr, MD	1
Choudhury, ME; Kubo, M; Nagai, M; Nishikawa, N; Nomoto, M; Yabe, H	1
Buckley, B; Sonsalla, PK; Winnik, B; Wong, LY	1
Asano, T; Hikawa, R; Takahashi, R; Uemura, MT; Yamakado, H	1

Other Studies

6 other study(ies) available for 3,4-dihydroxyphenylacetic acid and zonisamide

Article	Year
Effects of zonisamide on extracellular levels of monoamine and its metabolite, and on Ca2+ dependent dopamine release. Epilepsy research, 1992, Volume: 13, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anticonvulsants; Biogenic Monoamines; Calcium; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Hippocampus; Homovanillic Acid; Isoxazoles; Male; Rats; Rats, Wistar; Zonisamide	1992
Effects of zonisamide on dopaminergic system. Epilepsy research, 1995, Volume: 22, Issue:3 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anticonvulsants; Brain Chemistry; Dihydroxyphenylalanine; Dopamine; Enzyme Inhibitors; Extracellular Space; Hippocampus; Hydrazines; Isoxazoles; Male; Microdialysis; Monoamine Oxidase; Neostriatum; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase; Zonisamide	1995
Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity. Journal of neural transmission (Vienna, Austria : 1996), 2004, Volume: 111, Issue:6 Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Homovanillic Acid; Isoxazoles; Levodopa; Microdialysis; Oxidopamine; Parkinson Disease; Rats; Zonisamide	2004
Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP. Journal of pharmacological sciences, 2009, Volume: 110, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anticonvulsants; Biogenic Amines; Brain Chemistry; Callithrix; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Homovanillic Acid; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neostriatum; Neurons; Selegiline; Zonisamide	2009
The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Experimental neurology, 2010, Volume: 221, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antioxidants; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Glutathione; Isoxazoles; Male; Mass Spectrometry; Mice; Monoamine Oxidase; MPTP Poisoning; Regression, Psychology; Tyrosine 3-Monooxygenase; Zonisamide	2010
Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity. Neuroscience research, 2017, Volume: 124 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Astrocytes; Brain; Dopamine; Exploratory Behavior; Homovanillic Acid; Isoxazoles; Locomotion; Male; Mice, Inbred C57BL; Monoamine Oxidase; Neurons; Parkinson Disease; Social Behavior; Zonisamide	2017